AU2016275619B2 - Adenovirus polynucleotides and polypeptides - Google Patents

Adenovirus polynucleotides and polypeptides Download PDF

Info

Publication number
AU2016275619B2
AU2016275619B2 AU2016275619A AU2016275619A AU2016275619B2 AU 2016275619 B2 AU2016275619 B2 AU 2016275619B2 AU 2016275619 A AU2016275619 A AU 2016275619A AU 2016275619 A AU2016275619 A AU 2016275619A AU 2016275619 B2 AU2016275619 B2 AU 2016275619B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016275619A
Other languages
English (en)
Other versions
AU2016275619A1 (en
Inventor
Virginia Ammendola
Stefano Colloca
Riccardo Cortese
Fabiana GRAZIOLI
Alfredo Nicosia
Alessandra Vitelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510357.5A external-priority patent/GB201510357D0/en
Priority claimed from PCT/EP2015/063248 external-priority patent/WO2015189425A1/en
Priority claimed from GBGB1514772.1A external-priority patent/GB201514772D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2016275619A1 publication Critical patent/AU2016275619A1/en
Priority to AU2019202081A priority Critical patent/AU2019202081B2/en
Application granted granted Critical
Publication of AU2016275619B2 publication Critical patent/AU2016275619B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016275619A 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides Active AU2016275619B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019202081A AU2019202081B2 (en) 2015-06-12 2019-03-26 Adenovirus polynucleotides and polypeptides

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1510357.5 2015-06-12
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides
AUPCT/EP2015/063248 2015-06-12
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations
GBGB1514772.1A GB201514772D0 (en) 2015-08-19 2015-08-19 Adenovirus polynucleotides and polypeptides
GB1514772.1 2015-08-19
PCT/EP2016/063329 WO2016198621A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019202081A Division AU2019202081B2 (en) 2015-06-12 2019-03-26 Adenovirus polynucleotides and polypeptides

Publications (2)

Publication Number Publication Date
AU2016275619A1 AU2016275619A1 (en) 2018-01-04
AU2016275619B2 true AU2016275619B2 (en) 2019-09-19

Family

ID=57503533

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016275619A Active AU2016275619B2 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides
AU2016275601A Abandoned AU2016275601A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides
AU2019202081A Active AU2019202081B2 (en) 2015-06-12 2019-03-26 Adenovirus polynucleotides and polypeptides
AU2019271972A Ceased AU2019271972B2 (en) 2015-06-12 2019-11-27 Adenovirus polynucleotides and polypeptides

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016275601A Abandoned AU2016275601A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides
AU2019202081A Active AU2019202081B2 (en) 2015-06-12 2019-03-26 Adenovirus polynucleotides and polypeptides
AU2019271972A Ceased AU2019271972B2 (en) 2015-06-12 2019-11-27 Adenovirus polynucleotides and polypeptides

Country Status (13)

Country Link
US (4) US11254710B2 (enExample)
EP (2) EP3307313A1 (enExample)
JP (2) JP6983665B2 (enExample)
KR (2) KR102535670B1 (enExample)
CN (2) CN107921118B (enExample)
AU (4) AU2016275619B2 (enExample)
BE (1) BE1024420B1 (enExample)
BR (1) BR112017026523A2 (enExample)
CA (1) CA2988654A1 (enExample)
EA (1) EA038402B9 (enExample)
IL (2) IL256069B2 (enExample)
MX (2) MX2017016105A (enExample)
WO (2) WO2016198599A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102535670B1 (ko) 2015-06-12 2023-05-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN110036020A (zh) * 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3655539A1 (en) 2017-07-21 2020-05-27 GlaxoSmithKline Biologicals S.A. Chikungunya virus antigen constructs
CA3084346A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
CA3079048A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
KR20200066349A (ko) 2017-10-16 2020-06-09 글락소스미스클라인 바이오로지칼즈 에스.에이. 복제 가능 아데노바이러스 벡터
EP3697902A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
EP3704139A1 (en) * 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
MX2020006225A (es) 2017-12-20 2020-12-07 Glaxosmithkline Biologicals Sa Constructos antigenicos del virus de epstein-barr.
CN112638936A (zh) * 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3824090A4 (en) * 2018-06-25 2022-06-01 Akouos, Inc. METHODS OF TREATING HEARING LOSS AND/OR LOSS OF VISION ASSOCIATED WITH CLRN1
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
US11713469B2 (en) * 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
WO2021229473A1 (en) 2020-05-14 2021-11-18 Glaxosmithkline Biologicals Sa Viral biosensors
IL326497A (en) * 2023-08-11 2026-04-01 Joint Stock Company «Biocad» Adapted sequence of the adenovirus E2A gene for the creation of vectors based on ADENO-ASSOCIATED VIRUSES derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
CZ304169B6 (cs) 2001-06-22 2013-12-04 The Wistar Institute Of Anatomy And Biology Replikacne defektní opicí adenovirový vektor, zpusob jeho prípravy a lécivo, imunogenní kompozice a vakcína obsahující rekombinantní adenovirus
HU230364B1 (hu) * 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7205342B2 (en) * 2003-10-10 2007-04-17 General Electric Company Poly(arylene ether) composition and method of molding
ES2647491T3 (es) * 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Vectores del alfavirus para las vacunas del virus de la gripe
NZ581306A (en) * 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EA200702190A1 (ru) * 2005-05-12 2008-04-28 Глаксо Груп Лимитед Вакцинная композиция
JP5475279B2 (ja) * 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
CA2679410C (en) * 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
PT2220242T (pt) * 2007-11-28 2017-04-03 Univ Pennsylvania Adenovírus símio da subfamília b sadv-28,27,-29,-32,-33 e -35 e suas utilizações
KR101761691B1 (ko) * 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
EP2250255A2 (en) * 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
AU2009254168A1 (en) 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of HCV infections
CA2749325C (en) * 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010138675A1 (en) * 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
KR20120052369A (ko) * 2009-07-31 2012-05-23 팍스박스, 인코포레이티드 아데노바이러스계 벡터
WO2011130627A2 (en) * 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US20120328605A1 (en) 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
FR2978457A1 (fr) * 2011-07-27 2013-02-01 Univ Paris Diderot Paris 7 Composes contenant un vecteur viral a specificite hepatique et presentant une activite anti-inflammatoire
BR112014008167B1 (pt) * 2011-10-05 2022-05-24 Genvec Inc Adenovírus ou vetor adenoviral e composição os compreendendo
CN103239734B (zh) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
MY169352A (en) * 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
MX2015006377A (es) * 2012-11-20 2015-07-21 Glaxosmithkline Biolog Sa Trimeros prefusion de f de vsr.
DE102012221236A1 (de) 2012-11-21 2014-05-22 Zf Friedrichshafen Ag Getriebe
GB201303406D0 (en) * 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CN103937835A (zh) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 一种基于腺病毒AdC68的表达载体及其构建方法
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
KR102535670B1 (ko) 2015-06-12 2023-05-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof

Also Published As

Publication number Publication date
US20220204566A1 (en) 2022-06-30
WO2016198599A1 (en) 2016-12-15
KR102535670B1 (ko) 2023-05-22
CA2988481A1 (en) 2016-12-15
EA201792651A1 (ru) 2018-06-29
MX2017016105A (es) 2018-05-15
US20200140886A1 (en) 2020-05-07
WO2016198621A1 (en) 2016-12-15
MX2017016101A (es) 2018-02-21
KR20180011265A (ko) 2018-01-31
EA038402B9 (ru) 2021-09-22
JP2018523980A (ja) 2018-08-30
KR20180012857A (ko) 2018-02-06
AU2019202081A1 (en) 2019-04-18
BE1024420A1 (fr) 2018-02-12
AU2019271972A1 (en) 2019-12-19
JP2018524977A (ja) 2018-09-06
IL256069A (en) 2018-01-31
IL256121B2 (en) 2023-02-01
CA2988654A1 (en) 2016-12-15
CN107921118B (zh) 2022-11-08
AU2016275601A1 (en) 2018-01-18
AU2019202081B2 (en) 2021-09-23
CN108025058B (zh) 2022-12-16
US20220220157A1 (en) 2022-07-14
BR112017026523A2 (pt) 2018-08-14
IL256121B (en) 2022-10-01
IL256069B2 (en) 2023-07-01
AU2016275619A1 (en) 2018-01-04
EP3307314A1 (en) 2018-04-18
IL256069B1 (en) 2023-03-01
EA038402B1 (ru) 2021-08-23
EP3307313A1 (en) 2018-04-18
JP6873054B2 (ja) 2021-05-19
JP6983665B2 (ja) 2021-12-17
AU2019271972B2 (en) 2022-03-31
US11254711B2 (en) 2022-02-22
BE1024420B1 (fr) 2018-02-19
CN108025058A (zh) 2018-05-11
US20180170972A1 (en) 2018-06-21
IL256121A (en) 2018-02-28
US11254710B2 (en) 2022-02-22
CN107921118A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
US11795478B2 (en) Adenovirus polynucleotides and polypeptides
AU2019202081B2 (en) Adenovirus polynucleotides and polypeptides
US20230158134A1 (en) Chimpanzee adenovirus constructs with lyssavirus antigens
US11702674B2 (en) Simian adenovirus vectors comprising the ChAd-157 fiber protein
CA2988481C (en) Adenovirus polynucleotides and polypeptides
EA042571B1 (ru) Полинуклеотиды и полипептиды аденовируса
EA039001B1 (ru) Аденовирусные полинуклеотиды и полипептиды

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)